» Articles » PMID: 27349588

[Aftercare of Patients After MitraClip® Implantation]

Overview
Journal Herz
Date 2016 Jun 29
PMID 27349588
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Many patients with moderate to severe mitral regurgitation cannot be subjected to surgical therapy due to their multimorbidity. For these patients, MitraClip® implantation is a therapeutic alternative.The aim of this article is to present recommendations for treatment after a MitraClip® procedure. For this purpose, a selective literature review has been carried out based on the current literature, notably on national and international guidelines.After a MitraClip® procedure, rehabilitation is indicated because of the underlying heart failure as well as the treatment of a heart valve. Here, optimization of drug therapy, implementation of standardized heart failure training, the initiation of strength and endurance training and psychosocial support are initiated. Patients will be briefed on endocarditis prophylaxis lasting for at least six months. Furthermore, according to current guidelines, treatment with ACE inhibitors, beta-blockers and aldosterone antagonists are optimized. A special feature is anticoagulation, which is currently empirically accounted for and performed in sinus rhythm typically for four weeks of dual antiplatelet therapy (aspirin and clopidogrel) followed by a monotherapy with aspirin. In atrial fibrillation, lifelong oral anticoagulation is indicated combined with a platelet aggregation inhibitor for four weeks.In particular, echocardiographic control in the rehabilitation clinic and by cardiologists has to be focused on a residual atrial septal defect, the transmitral gradient and a residual mitral regurgitation.

Citing Articles

Feasibility of inpatient cardiac rehabilitation after percutaneous mitral valve reconstruction using clipping procedures: a retrospective analysis.

Schmidt T, Kowalski M, Bjarnason-Wehrens B, Ritter F, Monnig G, Reiss N BMC Sports Sci Med Rehabil. 2022; 14(1):120.

PMID: 35787297 PMC: 9254646. DOI: 10.1186/s13102-022-00517-y.


Real-world anticoagulatory treatment after percutaneous mitral valve repair using MitraClip: a retrospective, observational study on 1300 patients.

Hohmann C, Ludwig M, Walker J, Iliadis C, Schipper J, Baldus S Clin Res Cardiol. 2022; 111(8):889-899.

PMID: 35220447 PMC: 9334399. DOI: 10.1007/s00392-022-01988-2.

References
1.
Klein A, Burstow D, Tajik A, Zachariah P, Taliercio C, Taylor C . Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr. 1990; 3(1):54-63. DOI: 10.1016/s0894-7317(14)80299-x. View

2.
Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

3.
Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J . MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012; 14(9):1050-5. DOI: 10.1093/eurjhf/hfs079. View

4.
Seeburger J, Borger M, Falk V, Kuntze T, Czesla M, Walther T . Minimal invasive mitral valve repair for mitral regurgitation: results of 1339 consecutive patients. Eur J Cardiothorac Surg. 2008; 34(4):760-5. DOI: 10.1016/j.ejcts.2008.05.015. View

5.
Bursi F, Barbieri A, Grigioni F, Reggianini L, Zanasi V, Leuzzi C . Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail. 2010; 12(4):382-8. DOI: 10.1093/eurjhf/hfq014. View